Iterum Therapeutics enters commercialization agreement with EVERSANA for ORLYNVAH in US

Iterum Therapeutics plc

Eversana will be exclusive provider of sales, marketing, logistics, regulatory, and medical affairs services for ORLYNVAH.
ITUS retains legal, regulatory, manufacturing, and books sales; pays fees and expenses per statements of work.
Term is 5 years from commercial launch; either party can terminate for material breach, insolvency, or certain law changes.
ITUS or change-of-control counterparty may terminate upon paying specified fees; Eversana can terminate if ORLYNVAH is withdrawn.
Agreement includes customary confidentiality, indemnification, and liability limitations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.